Female doctor with a stethoscope advising a clinical trial participant.

Immunic Therapeutics

Developing Selective
Oral Drugs in Immunology

Immunic is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.

About Us

Advanced Development Pipeline

Differentiated Programs in Clinical Development

We are developing orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases.

About Our Pipeline

Treating Multiple Sclerosis

Elevate the Standard of Care With a Holistic Solution for Multiple Sclerosis Patients

Our mission is to develop high-quality, oral treatment options with comprehensive therapeutic efficacy and outstanding safety and tolerability for patients with multiple sclerosis.

About Vidofludimus Calcium

Treating Celiac Disease

Making New, Convenient, Oral Treatment Options Available to Celiac Disease Patients

We aim to offer new, efficacious, safe and well-tolerated orally available treatment options to patients suffering from celiac disease in order to improve their lives by eliminating the debilitating symptoms of the disease.

About IMU-856

Latest News

View All

May 2, 2025

Immunic to Participate in Scientific and Industry Conferences in May

April 30, 2025

Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

April 10, 2025

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

“My life’s work revolves around leading companies to successfully develop and commercialize therapeutics that vastly improve the lives of patients suffering from debilitating diseases. Demanding excellence is paramount to success.”

Dr. Daniel Vitt

Chief Executive Officer and Director

“I have been so fortunate to spend my professional career in the pharmaceutical industry, where I have had the opportunity to positively impact the lives of countless human beings living with serious diseases. There is nothing more rewarding than developing a new medicine and can bring hope where there was no hope. This is our ultimate goal here at Immunic, to address unmet needs for individuals living with chronic inflammatory and autoimmune diseases.”

Jason Tardio

President and Chief Operating Officer

“It is my passion to work with emerging companies to develop ground-breaking technologies. Dedicated, dynamic teams can achieve a lot together when they share mutual respect and empower each other to bring out their best. Or, as the old African proverb says: If you want to go fast, go alone. If you want to go far, work together.”

Dr. Andreas Muehler

Chief Medical Officer

“Beautiful science should be translated into a better life for patients, otherwise, it’s still beautiful, but useless.”

Dr. Hella Kohlhof

Chief Scientific Officer

“It is my passion to be a member of an emerging company working with a team of extremely talented people, all focused in the same direction, with the goal of bringing life changing therapies to patients.”

Glenn Whaley

Chief Financial Officer

“Having a positive impact on patients’ lives is the ultimate objective. As a team, we must seize the opportunities to maximize the potential of our programs so that we may also maximize the benefits for patients.“

Patrick Walsh

Chief Business Officer

“My focus is, not only, to review and approve documents but to collaborate with my amazing colleagues in order to make a substantial impact for patients while creating long-term value for our investors and other stakeholders.”

Inderpal Singh

General Counsel

“I have a personal, long-lasting commitment to make every day count for those who need it most. I am, therefore, grateful that at Immunic we have an innate sense of urgency to make a difference, turning scientific breakthroughs into therapies that offer hope, improved health outcomes and meaningful improvements that change patients’ lives.”

Werner Gladdines

Chief Development Officer

“I am truly honored to work with such a high-powered team on the pursuit of exciting new science. We aim to bring novel and meaningful therapeutic options to doctors and their patients with devastating inflammatory and auto-immune conditions. Each of our drug candidates is potentially best-in-class and targets a product profile designed to improve patients’ lives by combining the convenience of oral delivery, with robust efficacy and patient-friendly tolerability.“

Dr. Duane Nash

Executive Chairman